Inspire Medical Systems financials
$73.18+4.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $912.0M | $802.8M | $624.8M | $407.9M | $233.4M | $115.4M | $82.0M | $50.6M |
| Gross profit | $778.8M | $679.8M | $528.2M | $341.7M | $200.1M | $97.8M | $68.4M | $40.5M |
| Gross margin | 85.4% | 84.7% | 84.5% | 83.8% | 85.7% | 84.7% | 83.4% | 80.1% |
| Operating income | $51.0M | $36.1M | -$40.3M | -$47.6M | -$39.9M | -$56.2M | -$34.9M | -$20.4M |
| Net income | $145.4M | $53.5M | -$21.2M | -$44.9M | -$42.0M | -$57.2M | -$33.2M | -$21.8M |
| Net margin | 15.9% | 6.7% | −3.4% | −11.0% | −18.0% | −49.6% | −40.5% | −43.1% |
| Diluted EPS | $4.89 | $1.75 | $-0.72 | $-1.60 | $-1.54 | $-2.19 | $-1.40 | $-1.50 |
| EBITDA | $64.9M | $42.6M | -$37.4M | -$45.7M | -$38.6M | -$55.4M | -$34.4M | -$20.6M |
| Operating cash flow | $117.0M | $130.2M | $24.7M | $11.6M | -$20.1M | -$53.0M | -$32.8M | -$18.7M |
| Free cash flow | $78.5M | $91.1M | $1.0M | $2.5M | -$24.8M | -$55.5M | -$35.6M | -$18.9M |
| Diluted shares | 29.8M | 30.5M | 29.3M | 28.1M | 27.3M | 26.1M | 23.8M | 14.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $104.8M | $150.2M | $185.5M | $441.6M | $214.5M | $190.5M |
| Short-term investments | $203.5M | $295.4M | $274.8M | $9.8M | $0.00 | $43.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $25.0M | $24.7M |
| Total assets | $907.3M | $808.4M | $676.8M | $564.9M | $295.1M | $281.2M |
| Total liabilities | $126.2M | $118.7M | $104.3M | $68.9M | $66.0M | $51.4M |
| Shareholders' equity | $781.2M | $689.7M | $572.5M | $496.0M | $229.0M | $229.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology